

Remarks/Arguments

Claims 1-4 are withdrawn; claims 5, 7, 9, 11 and 13-20 are pending in the application; and claims 6, 8, 10, and 12 are canceled. Accordingly, claims 5, 7, 9, 11 and 13-20 are presented for examination on the merits.

I. Rejection of Claims Under 35 U.S.C. § 112, First Paragraph

Claims 5, 7, 9, 11 and 13-20 stand rejected under 35 U.S.C. § 112, first paragraph, because the specification allegedly does not enable prevention of seizures. The Examiner states at page 2 of the Office Action that the “one example” provided in the specification is not representative to support “prevention” of seizures. The Examiner also states that no correlation has been made between animal (rat) studies and humans in respect to seizure prevention.

This rejection is respectfully traversed as follows.

The “one example” that is provided in the specification is a study involving twenty rats that were pretreated with agmatine before seizures were induced. The study involved the Maximal Electroshock Seizure (MES) test, which is a standard animal test used by those of skill in the art to test compounds for seizure control. (See Stables and Kupferberg, *The NIH Anticonvulsant Drug Development (ADD) Program: Preclinical Anticonvulsant Screening Project*, www.ninds.nih.gov/funding/research/asp/addadd_review.pdf (copy enclosed)). As can be seen from the enclosed NIH review, “The MES is a model for generalized tonic-clonic seizures. It is highly reproducible with consistent endpoints. The behavior and electrographic seizures generated in this animal model are consistent with the human disorder. (Swinyard et al., 1989). This model identified those compounds which prevent seizure spread.” (page 3) Clearly, the field of neurobiology has accepted the rat MES model as a correlative of seizure in humans.

The Examiner objects to the “one example” set forth in the specification because it is “not representative,” but provides no explanation for this statement. For example, the examiner has pointed out no errors or deficiencies in the testing. Moreover, the study involved twenty rats, which is sufficient to establish statistical significance, and utilized a standard test that is noted for its reproducibility and consistent results. It is respectfully submitted that this study clearly establishes the ability of the test compound, agmatine, to prevent seizure spread.

Accordingly, the rejection of claims 5, 7, 9, 11 and 13-20 under 35 U.S.C. § 112, first paragraph, is respectfully traversed.

II. Rejection of Claims Under 35 U.S.C. § 103(a)

Claims 5, 7, 9, 11 and 13-20 stand rejected under 35 U.S.C. § 103(a) as being unpatentably obvious “for the reasons set forth on pages 3 and 4 of the office action of May 5, 2005,” which address a rejection of the claims under 35 U.S.C. § 103(a) over Zubay et al. in view of Rajasekaran.

It is respectfully submitted that the combination of cited prior art is improper, and does not render the claimed invention *prima facie* obvious. The examiner relies on Uzbay as teaching that agmatine’s effects on alcohol withdrawal are mediated through the NOS pathway by blocking the enzyme, NOS. The examiner also asserts that Rajasekaran teaches that the underlying mechanism for anticonvulsant activity is NO inhibition. The examiner then concludes that it would have been obvious to one of skill in the art to modify Uzbay’s teaching in view of Rajasekaran to use agmatine to treat seizures associated with epilepsy.

This rejection is respectfully traversed as follows. As discussed in detail in the response filed November 7, 2005, Uzbay reports results of a study in which the effects of agmatine on alcohol withdrawal symptoms, including tremors, wet dog shakes, agitation, and seizures, were

determined. Uzbay reports that agmatine lessened some of the symptoms of alcohol withdrawal, such as wet dog shakes and tremors, but these symptoms are not associated with epilepsy and are not relevant to the present claims. When addressing seizures associated with alcohol withdrawal, Uzbay concludes that “the inhibitory effect of agmatine did not reach a statistically significant level.” (p. 155, § 3.3). However, the examiner continues to ignore the significance of this statement. This reference teaches a **failed attempt** to treat seizures with agmatine, and not does not suggest that agmatine is a useful treatment for seizures in general. Clearly, the primary reference teaches away from the use of agmatine to treat alcohol-related seizures, and more particularly, seizures in general. On this basis alone, the skilled practitioner would not be motivated to use agmatine for treatment of seizures associated with epilepsy.

Further, the combination of Rajasekaran with Uzbay does not cure the deficiencies of the primary reference. To establish a *prima facie* case of obviousness, the examiner must show that there is some suggestion or motivation in the cited prior art to modify or combine the teachings of the references. However, in the present case, the primary reference teaches that agmatine does not have a statistically significant effect on alcohol withdrawal related seizures, and therefore is not be accepted as valid by those of ordinary skill in the art, yet the examiner asserts that it would have been obvious to modify the primary reference to use agmatine to treat seizures associated with epilepsy. This combination of art is clearly improper since the primary reference teaches away from the use of agmatine to treat seizures.

Moreover, even if one of skill in the art were motivated to combine the references as suggested by the examiner, the combination of art does not establish a *prima facie* case of obviousness. In order to establish a *prima facie* case of obviousness, the examiner must show that the prior art teaches a reasonable expectation of success of the claimed method. *Amgen, Inc. v.*

Chugai Pharmaceutical Co., 927 F.2d 1200, 1207-08. The prior art cited by the examiner fails to show an expectation of success, and instead teaches that at the time of the invention, little was known as to the cause of seizures or how any treatment actually worked.

In the abstract to the Rajasekaran reference, it is stated that “The role of nitric oxide (NO) in seizures remain debated,” yet the examiner asserts that the “known effects” of agmatine on NO synthesis render the claimed invention obvious. In the Discussion and Conclusion sections of the Rajasekaran poster, the authors state that NO inhibition “may prevent seizures;” the “anticonvulsant activity of L-arginine may not essentially be mediated by the NOS pathway;” and “The anticonvulsant activity of L-arg may be direct (reference deleted) or a product of its metabolism such as agmatine (reference deleted) or to the possible accumulation of L-arg per se (reference deleted). Clearly, this reference teaches that at the time of the invention, there was a good deal of confusion in regards to the cause of seizures, and in particular, the pathways by which seizures are generated.

The confusion with regard to the cause of seizures and the conclusions drawn by Rajasekaran makes it abundantly clear that there is nothing predictable or obvious about the treatment of seizures. Rajasekaran merely speculates as to causes and possible treatments for seizures, and this speculation amounts to nothing more than a suggestion to try any of the treatments proposed in this non-peer review poster.

Moreover, Rajasekaran does not suggest that any one of the speculative treatments may be more successful than the others, and significantly, there are no data in this reference that suggest that administration of agmatine will successfully treat or prevent seizures associated with epilepsy. Thus, the combined teachings of Rajasekaran and Uzbay, **which teaches that agmatine did not have a statistically significant effect on seizures, i.e., did not demonstrate an effect that would be**

accepted as valid by the scientific community (those of ordinary skill in the art), do not lead to the present invention. Instead, this combination of prior art clearly shows that at the time of the invention, little was known about the cause of seizures, and even less about treatment of seizures. This combination of prior art simply fails to render the claimed invention obvious.

For the foregoing reasons, it is submitted that the claims 5, 7, 9, 11 and 13-20 are patentable over the teachings of Uzbay in combination with Rajasekaran. Accordingly, favorable reconsideration of the claims is requested in light of the preceding amendments and remarks. Allowance of the claims is earnestly solicited.

If there are any outstanding issues that might be resolved by an interview or an Examiner's amendment, the Examiner is requested to call Applicants' attorney at the telephone number shown below.

To the extent necessary, a petition for an extension of time under 37 C.F.R. § 1.136 is hereby made. Please charge any shortage in fees due under 37 C.F.R. § 1.17 and due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Judith Toffenetti

Registration No. 39,048

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 202.756.8000 CKW:ckw
Facsimile: 202.756.8087
Date: December 21, 2006.

**Please recognize our Customer No. 20277
as our correspondence address.**

Chapter 16

The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project

James P. Stables and Harvey J. Kupferberg

*Epilepsy Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health,
Bethesda, MD 20892, USA*

Summary

Summary reports are written for those compounds that have undergone multilevel evaluations. A report analyzes and interprets the generated data, and also compares the candidate compound's pharmacodynamic and pharmacokinetic profile to that of current clinically effective drugs. Annually, approximately ten promising compounds are considered for further development by the ADD Program. If a compound appears to have potential, the ADD Program collaborates with the pharmaceutical or academic sponsor in scheduling further preclinical and clinical evaluations.

Introduction

Many patients with epilepsy fail to experience adequate control of their seizures, despite the optimal use of available anti-epileptic drugs marketed in the United States. Other patients do so only at the expense of significant toxic side effects. Since 1975, the Epilepsy Branch of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, through its Antiepileptic Drug Development (ADD) Program, has collaborated with the pharmaceutical industry in developing new therapeutic agents for the treatment of seizure disorders. In 1993, felbamate, the first new drug in nearly two decades, was approved for sale in the United States. Felbamate's development was a collaborative effort of both the pharmaceutical sponsor and ADD Program. Two other drugs, topiramate and remacemide were identified in the Branch's preclinical evaluation and are now in late clinical development. Topiramate is being developed worldwide and received market approval in the UK in 1995. Several other drugs, losigamone (Schwabe, Germany), D-23129 (Asta/AWD Germany), D2916 (Biocodex, France), CGP 33101 (Ciba-Geigy, Switzerland) and BW 534U (Wellcome-Glaxo, USA) are now in early clinical development.

The ADD Program boasts of both a preclinical and clinical trials component. The preclinical component consists of drug discovery and toxicology elements. These elements are carried out under contracts to the NIH. For the past two decades, the drug discovery project, known as 'The Anticonvulsant Screening Project' (ASP), has successfully identified numerous lead compounds for development. The ADD

Program's Toxicology Project provides additional support incentives to encourage industry's management to continue long term development of the very best compounds.

The initial preclinical evaluation of a compound's anticonvulsant potential is accomplished by screening new submissions through a series of *in vivo* and *in vitro* tests. Comparative decisions are made at each step in this multilevel testing process until the best compounds are selected. One of the unique aspects of the ASP is the diversity of chemical entities submitted for screening. Unlike an individual company that utilizes in-house drug libraries, the ASP receives compounds from a large and diverse group of suppliers from around the world. Over 300 worldwide suppliers have submitted their compounds to the ADD Program for evaluation. In recent years, ten to fifteen new suppliers have joined the ADD Program annually. At the present time, the ADD Program has 120 industrial and 196 academic suppliers providing compounds for evaluation. This broad spectrum of participants provides a large variety of new chemical entities. The diversity of structural submissions provides a unique opportunity to increase the chances of discovering compounds with new mechanisms of actions. All compounds of interest are compared and contrasted with known clinically effective drugs. It is believed that this process assures that the most novel drugs are proposed for clinical development.

The ASP was initiated at the University of Utah in the early 1974 under a NINDS contract. Over the past twenty years, an average of 865 new chemical entities have been screened annually for anticonvulsant activity. In early 1994, the ASP's multilevel testing procedures were revised from previous descriptions of the ADD Program's Screening Project (Kupferberg, 1989). The protocol revisions include both mechanistic and 'seizure type' models for evaluating a compound's anticonvulsant potential. Only a small number of compounds actually progress beyond the early identification phases and enter into the more advanced and complex evaluation procedures.

Compounds submitted by industrial suppliers enter into the **ADD Program** under a confidentiality agreement between the NIH and the supplier. This agreement assures the strict confidentiality of the compounds source, chemical structure and evaluation results. The Government can not release or publish any data without prior written approval from the sponsor. No therapeutic areas other than epilepsy are evaluated during the screening process. Compounds are given a unique identification code prior to its shipment to the ASP. The confidential data generated from the ASP's multilevel evaluation is filed with the Epilepsy Branch and then returned directly to the compound's sponsor. The sponsor has the final responsibility in the determination of their compound's development. In most cases, the sponsor seeks advice from the ADD Programs's staff in making their development decisions.

Anticonvulsant screening

A singular approach to identifying potentially useful drugs can not be used in a drug discovery program such as the ADD Program. For example, a **mechanistic** approach assumes a specific mechanism(s) for seizure initiation, propagation, and amelioration. Examples of this approach would be to identify compounds that work via inhibition of excitatory amino acid mediated excitation or enhancement of GABA-mediated inhibitory transmission. This approach also assumes that an appropriate model exists (usually an *in vitro* model). To some extent this approach limits the discovery of mechanistically novel substances. The advantage of this approach is that a large number of compounds can be evaluated in a short period of time, with limited amounts of material and without the use of large numbers of animals.

The **non-mechanistic** approach has advantages and disadvantages. Non-mechanistic seizure models have clearly defined endpoints. Examples of such endpoints are the inhibition of the tonic hindlimb extension phase, following electrically induced seizures or clonic seizures following administration of seizure producing doses of chemoconvulsants. These methods require limited technical expertise and they permit a direct comparison of the anticonvulsant profile of a new drug to that of the 'clinically effective therapeutic agents'. Unfortunately, this approach provides little pertinent information regarding an active compound's mechanism of action, which is highly desirable for making development decisions.

The ASP uses both electrical (MES) and chemical induced seizures (scPTZ) for its initial screening procedures. The animals are 'normal' and not genetically predisposed to seizures. While the neuronal sensitivity of normal mice to anticonvulsants may be different than in epileptic animals, these models afford certain advantages over genetic epileptic prone animal models for the following reasons: (1) They are suited to routine screening of a large number of potential anticonvulsants. (2) Normal animals are less expensive than are the inbred genetic animals. (3) Genetically epileptic prone rodents exhibit a greater number of false positive responses to non-anticonvulsant drugs. (4) The historical database for normal animals is extremely large allowing for large-scale comparisons.

The '**seizure-type** model' approach is limited because a limited number of 'Epilepsies' are associated with an animal model. The models that are available require a high degree of technical expertise, are costly and labor intensive. With such models, drugs for symptomatic epilepsy are not readily identified, whereas those for the generalized epilepsies are much more easily identified.

The Anticonvulsant Screening Project (ASP)

The ASP uses a combination mechanistic, non-mechanistic and 'seizure-type' approach to identify potential compounds for the treatment of seizures. The initial screening procedures are broad and non-mechanistic and serve to identify CNS and minimal neurotoxic activity of the compound. Once identified in the initial non-mechanistic screens, a compound's activity is then differentiated using '**syndrome-specific**' animal seizure models. Finally, advanced studies are used to identify proconvulsant potential of compounds, tolerance to the anticonvulsant effects, and possible molecular targets that can contribute to a compound's mechanism of action.

Primary evaluation

The ASP initially evaluates anticonvulsant activity for newly submitted compounds following intraperitoneal (i.p.) administration in mice and oral administration in rats. Two convulsant tests (MES and scPTZ) and a toxicity screen (rotarod in mice, positional sense and gait in rats) are employed for primary evaluation.

The Maximal Electroshock Seizure (MES) or Maximal Seizure Pattern Test

The MES is a model for generalized tonic-clonic seizures. It is highly reproducible with consistent endpoints. The behavioral and electrographic seizures generated in this model are consistent with the human disorder (Swinyard *et al.*, 1989). This model identifies those compounds which prevent seizure spread.

In the MES test, an electrical stimulus of 0.2 s in duration (50 mA in mice and 150 mA in rat at 60Hz) is delivered via corneal electrodes primed with an electrolyte solution containing an anesthetic agent. Mice are tested at 30 minutes and 4 hours following doses of 30, 100 and 300 mg/kg of test compound. Other doses can be used if previously known pharmacology merits deviation. Rats are tested at time intervals between 0.25 and 4 hours following a standard oral dose of 30 mg/kg. Abolition of the hindlimb tonic extensor component indicates the test compound's ability to inhibit MES-induced seizure spread (White *et al.*, 1995a; White *et al.*, 1995b; Swinyard *et al.*, 1989).

The subcutaneous Pentylenetetrazol (Metrazol) Seizure Test (scPTZ)

This is a model that primarily identifies compounds that raise seizure threshold. The behavioral seizure produced is not typical of absence epilepsy but clonic in nature. Like other rodent models of absence seizures, PTZ induced seizures are potentiated by GABA agonist. With some minor exceptions, the pharmacological profile of the scPTZ seizure model is consistent with the human condition (Snead, 1992; Swinyard *et al.*, 1989)

The scPTZ test utilizes a dose of pentylenetetrazol (85 mg/kg in Carworth Farms No. 1 mice and 70 mg/kg in Sprague-Dawley rats). This produces clonic seizures lasting for a period of at least five seconds in 97 per cent (CD₉₇) of animals tested. At the anticipated time of testing the convulsant is administered subcutaneously. The test compound is administered intraperitoneally in mice and orally in rats. Animals are observed over a 30 minute period. Absence of clonic spasms in the observed time period indicates a compound's ability to abolish the effect of pentylenetetrazol on seizure threshold (Swinyard *et al.*, 1989). All clinically active anticonvulsants have been found to be protective in at least one of these two tests.

Minimal neurotoxicity

Toxicity induced by a compound is detected in mice using the standardized rotarod test described by Dunham & Miya (1957). Untreated control mice, when placed on a 6 r.p.m. rotation rod, can maintain their equilibrium for a prolonged period of time. Neurological impairment can be demonstrated by the inability of a mouse to maintain equilibrium for one minute in each of three successive trials.

Rats are examined for behavioral toxicity by the positional sense test and a gait and stance test. In the positional sense test, one hind leg is gently lowered over the edge of a table, whereupon the rat, experiencing neurological deficit, will fail to lift its leg quickly back to a normal position. In the gait and stance test, neurotoxicity is indicated by a circular or zigzag gait, ataxia, abnormal spread of the legs, abnormal posture, tremor hyperactivity, lack of exploratory behavior, somnolence, stupor or catalepsy.

Compounds that possess significant anticonvulsant activity in rats and mice and do not exhibit substantial neurotoxicity or death are considered for the ADD Program's multiphase evaluation to establish a compound's pharmacodynamic/pharmacokinetic profile.

During the past five years, over 4000 compounds have been evaluated by the ADD Program. Approximately 10 per cent of these compounds were active in the MES test following administration of doses as low as 30 mg/kg in mice. In the scPTZ test, 154 compounds were found to be active following i.p. administration of doses at or below 100 mg/kg in mice. In primary anticonvulsant screens for rats, 60

compounds produced complete protection against induced seizures in all animals in at least one of five time periods examined from 15 minutes to 4 hours at doses of 30 mg/kg.

Secondary evaluations

All quantitative *in vivo* anticonvulsant/toxicity evaluations of the most active compounds are conducted at a compound's time of peak pharmacodynamic activity (TPE). Groups of at least eight mice or rats receive various doses of the candidate compound until at least two points are established between the limits of 100 per cent protection or toxicity and 0 per cent protection or minimal toxicity. The 95 per cent confidence limits (95 per cent C.I.), slopes of the regression lines and standard errors of the slopes are calculated for each quantitative determination (Finney, 1971). Rats receive test compounds orally and mice intraperitoneally.

For the same five year period, 143 compounds had MES $ED_{50s} \leq 20$ mg/kg and approximately 50 compounds had scPTZ $ED_{50s} \leq 20$ mg/kg. As a number of active compounds were found in both species, discriminating questions and decision points were incorporated in an attempt to better identify lead compounds for further development and resource allotment.

Decision processes

Several considerations arise from the primary and secondary mouse screens. Does the compound produce death or possess proconvulsant potential? Is there significant separation between anticonvulsant activity and minimal neurotoxicity/death? If the compound is from a series, is it the most potent/least toxic? Is the compound's chemical structure unique? What is its duration of action? Finally, what kind of resources can be mobilized to assure the most expedient development.

From the early rat screens, the following questions can be posed. Does the compound produce complete protection (4/4) at 30 mg/kg at any time point? Does the compound produce neurotoxicity following oral administration? If not, should other routes of administration be used which may bypass possible absorption problems? If from a series, which compound is the most potent with the longest duration of activity? Is it structurally unique or similar to other anticonvulsants?

Tertiary/*in-vivo* evaluation

Lead compounds enter a more complex level of evaluation. The limited *in vivo* tests are used to elucidate at compound's inhibitory mechanism of action and therapeutic utility. The initial quantitative differential evaluations in mice include clonic seizures induced by the subcutaneous administration of bicuculline and picrotoxin (White, 1995b *et al.*, Swinyard *et al.*, 1989).

The candidate compound's anticonvulsant activity in a genetically seizure prone animal model is then determined. Several types of genetically seizure prone animals are available to evaluate a candidate's ability to block the tonic phase of the reflex epilepsy. Specific strains of mice, rats, baboon, gerbils and chickens (Locher, 1984) have been used to determine a compound's anticonvulsant activity. The genetically susceptible Frings strain (Frings, 1952; Swinyard *et al.*, 1963) is used by the ADD Program for this purpose. This strain differs from the seizure susceptible DBA/2 strain in that it maintains its reflex epilepsy potential throughout its life. Individual mice are placed in a plexiglass cylinder and exposed to a sound stimulus of 100 decibels (11 Hz) for 20s. Anticonvulsant testing occurs at the compound's previously determined time of peak activity. The seizures experienced by these animals are characterized by wild

running, followed by loss of righting reflex with forelimb and hindlimb tonic extension. A compound's pharmacologic efficacy is demonstrated by the abolition of the tonic hindlimb extension.

The **seizure-type** models used in the ADD Program's evaluation of anticonvulsant activity are: (1) **Hippocampal kindling** model of focal seizures and (2) **Gamma (γ)-hydroxybutyrate spike and wave** model of generalized absence seizures.

The hippocampal kindling model can be used to evaluate a compound's ability to affect both the **expression and acquisition** of focal seizures. The hippocampal kindling paradigm as described by Lothman and Williamson (Lothman, 1994) offers a distinct advantage over other kindling models. In particular, it is one of the only models wherein the temporal effects of a drug can be evaluated in a single animal. This procedure requires the surgical placement of bipolar electrodes in the ventral hippocampus of adult male Sprague-Dawley rats. Stage five behavioral seizures (Racine, 1972) are produced by using a stimulus consisting of a 50 Hz, 10 s train of 1 ms biphasic 200 μ A pulses delivered every 30 min for 6 hours (12 stimuli per day) on alternating days for a total of 60 stimulations (five stimulus days). Prior to evaluating a candidate's anticonvulsant activity, a drug free control period consisting of supramaximal stimulations are recorded to verify the stability of a stage five generalized seizure.

A single dose of the candidate compound is then administered intraperitoneally (i.p.), 15 min following the last control stimulation. The anticonvulsant activity of the drug is assessed every 30 min for three to four hours starting 15 min after administering the test material. After each stimulation, individual Racine seizure scores and afterdischarge durations are recorded. Rats are used again in drug trials after four to five drug- and stimulus-free days.

In the kindling acquisition study, drugs are tested for their ability to prevent the development of the kindled state in electrode implanted rats. The candidate compound is administered during the kindling procedure. For these studies, drug is administered at a predetermined time prior to the electrical stimulus. The dosing interval and the dose of the drug are based on the compound's activity observed in the acute seizure expression studies. Results from drug-treated animals are compared to those of saline-treated rats. This treatment is repeated on stimulus days two, three, four, and five. After a stimulus-free interval of one week, the effect of prior drug treatment on kindling acquisition is assessed by challenging the animal with the kindling stimulus protocol. The standardized kindling protocol is then carried out with the behavioral seizure score and afterdischarge duration recorded for each rat during three 'retest days'. Saline treated rats are fully kindled at the first stimulation following the one week stimulus-free period. An active compound would be expected to lower behavioral scores and afterdischarge duration compared to saline control rats. The suppression or lengthening of the delay in the acquisition of the kindled response may indicate that the candidate compound can act to prevent the development of seizures. Such compounds could be termed 'antiepileptogenic'.

γ -hydroxybutyrate spike wave model

Selected phenytoin-like candidate substances are further evaluated in rats by the γ -hydroxybutyrate (GHB) spike-wave model of absence (Snead, 1992). The GHB model, like the i.v. PTZ test, is utilized to ascertain the proconvulsant potential of test substances which possess a phenytoin-like anticonvulsant profile in other models. Generally, eight rats are treated orally with the dose of candidate substance that provides 97 per cent protection against MES seizures; at the TPE, 150 mg/kg of GHB is administered i.p. The EEG of individual rats is monitored for a period of two hours and the severity of spike-wave seizures

evaluated by computer analysis of the EEG. This is also an extremely useful model for verifying whether candidate substances with an ethosuximide-like profile will possess activity in another model of absence (Snead, 1992).

Proconvulsant evaluation

A compound that prevents seizure spread (active in the MES test), can lower seizure threshold at the same time (White, 1995a). Thus, this compound would have proconvulsant activity while at the same time prevent generalized tonic seizures. Mexiletine, a cardiac antiarrhythmic drug, is a potent MES compound, yet it lowers seizure threshold at doses slightly above the MES ED₅₀ in mice. The timed intravenous pentylenetetrazol seizure threshold test in mice identifies those MES compounds with proconvulsant potential (Orlof, 1949).

Mice are given the candidate substance intraperitoneally at the ED₅₀ and TD₅₀. At the time of maximal MES activity, an intravenous infusion of 0.5 per cent heparinized solution of pentylenetetrazol (0.34 ml/min) is started. The time to the appearance of the first myoclonic jerk and the subsequent sustained clonic seizure are the measured endpoints. Results are obtained for groups of ten treated and ten saline control mice and converted to the dose in mg/kg of PTZ necessary to produce the two endpoints. Proconvulsants lower the dose of PTZ required to produce the endpoint. Anticonvulsant drugs such as valproic acid, ethosuximide and phenobarbital increase the amounts of PTZ required to produce the above endpoints.

***In-vitro* mechanistic studies**

Two mechanistically related methods are used to evaluate a compound's interactions with excitatory (glutamate) and inhibitory (GABA) receptor gated ion channels. The methodology uses whole cell patch-clamp electrophysiological measurement on single mouse cortical neurons. Whole cell recordings are obtained from the primary cultured neurons using borosilicate glass electrodes as described by Hamill *et al.* (1981). Results from these studies provide the first insight into the molecular mechanisms of action of candidate substances. The *in vitro* actions of these experiments are then correlated with the data from the animal seizure models.

Tolerance and metabolism studies

Finally, subchronic administration studies are initiated in order to provide preliminary information regarding a compound's ability to produce tolerance, hepatotoxicity and effects on drug P-450 metabolism isozymes. The *in vivo* tolerance studies consist of administering the candidate compound orally for five days to rats and then comparing the anticonvulsant activity to animals receiving the compound acutely, following four days of saline treatment. These studies employ four groups of eight rats per group. Two groups are treated for four days with vehicle alone. Two groups receive different doses of active material for four days. On the fifth day, each drug treatment group and one saline treated group receives the oral ED₅₀ of the compound. The candidate compound's anticonvulsant activity for each group is determined. Activity in the chronically treated groups are compared to the acute treatment and saline control.

On day six, all groups are given hexobarbital (100 mg/kg) intraperitoneally and the sleeping times (time from loss to regaining of righting reflex) measured. The hexobarbital sleep time tests provides an assessment of hepatic drug metabolism. These data provide some indication of whether changes in observed anticonvulsant activity are due to either pharmacodynamic or pharmacokinetic interactions.

Treatment is continued for an additional day. The rats are then euthanized, blood collected and livers removed and weighed. The blood is allowed to clot and serum analyzed for alanine amino transferase (sALT) activity. Increased sALT may indicate possible liver damage. The excised livers are perfused in situ with saline, and homogenized in 0.25 M sucrose. Hepatic endoplasmic reticulum (i.e. microsomes) and cytosol are isolated following centrifugation. Microsomal cytochrome P-450 concentrations and both cytosol and several microsomal oxidative dealkylases, and transferases are then determined. Any metabolic enzyme induction is then correlated with any changes in anticonvulsant activity and hexobarbital sleep time.

References

- Dunham, M.S. & Miya, T.A. (1957): A note on a simple apparatus for detecting neurological deficit in rats and mice. *J. Amer. Pharmac. Assoc. Sci. Edit.* 46, 208-209.
- Finney, D.J. (1971): *Probit Analysis*, 3rd edn. London: Cambridge University Press.
- Frings, H. & Frings, M. (1952): Acoustical determinants of audiogenic seizure in laboratory mice. *J. Acoustal Soci.Amer* 24, 163-169.
- Hamil, O.P., Marty, A., Neher, E., Sakmann, B. & Sigworth, F. (1981): Improved patch clamp technique for high resolution current recordings from cells and cell free membranes. *Pflügers Arch.* 391, 85-100.
- Kupferberg, H.J. (1989): Antiepileptic drug development program: A cooperative effort of government and industry. *Epilepsia* 30 (suppl.1), S51-S56.
- Locher, W. & Meldrum, B. (1984): Evaluation of anticonvulsant drugs in genetic animal models of epilepsy. *Fed. Proc.* 43(2), 276-284.
- Lothman, E.W. & Williamson, J.M. (1994): Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapidly developing, transient kindling and a slowly developing, enduring kindling. *Brain Res.* 649, 71.
- Orlof, M.J., Williams, H.L. & Pfeiffer, C.C. (1949): Timed intervenous infusion of metrazol and strychnine for testing anticonvulsant drugs. *Proc. Soc. Exp. Biol. Med* 70, 254-257.
- Racine, R. J. (1972): Modification of seizure activity by electrical stimulation. II. Motor seizure. *Electroenceph. Clin. Neurophysiol.* 32, 282.
- Snead, O.C. (1992): Pharmacological models of generalized absence seizures in rodents. *J. Neural Transm. (Suppl)* 35, 7-19.
- Swinyard, E.A., Clark, L.D., Miyahara, J.T. & Wolf, H.H. (1963): Some Physiological Properties of Audiogenic Seizures in Mice and Their Alteration by Drugs. Procedures International Conference on Psychophysiology, Neuropharmacology, and Biochemistry of Audiogenic Seizures Paris, France: International Colloquium No. 112, 405-427.
- Swinyard, E.A., Woodhead, J.H., White, H.S. & Franklin, M.R. (1989): General principles: experimental selection, quantification, and evaluation of anticonvulsants. In: *Antiepileptic Drugs*, Third Edition R.H. Levy, R.H. Mattson, B. Melrum, J.K. Penry and F.E. Dreifuss eds, pp. 85-102. New York: Raven Press.
- White, H.S., Johnson, M., Wolf, H.H. & Kupferberg, H.J. (1995): The early identification of

anticonvulsant activity: role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. *Italian Journal of Science* 16, 73-77.

White, H.S., Woodhead, J.H. & Franklin, M.R. (1995); General principles: experimental selection, quantification, and evaluation of antiepileptic drugs. In: *Antiepileptic Drugs*, Fourth Edition, eds. R.H. Levy, R.H. Mattson and B.S. Meldrum pp. 99-110. New York: Raven Press.